Immix Biopharma announced a $125 million public offering shortly after interim Phase II NEXICART-2 results showed its BCMA-targeted CAR-T, NXC-201, delivered an 89% complete response rate among 45 patients with light-chain (AL) amyloidosis. The company expects a BLA submission next year after final study data. The financing highlights continuing investor demand for late-stage immuno-oncology and cell therapy programs, but the schedule places execution pressure on the remaining data package.